Asset Details
Do you wish to reserve the book?
Echinocandin Resistance in Candida
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Echinocandin Resistance in Candida
Do you wish to request the book?
Echinocandin Resistance in Candida
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Echinocandin Resistance in Candida
2015
Overview
Invasive fungal infections are an important infection concern for patients with underlying immunosuppression. Antifungal therapy is a critical component of patient care, but therapeutic choices are limited due to few drug classes. Antifungal resistance, especially among Candida species, aggravates the problem. The echinocandin drugs (micafungin, anidulafungin, and caspofungin) are the preferred choice to treat a range of candidiasis. They target the fungal-specific enzyme glucan synthase, which is responsible for the biosynthesis of a major cell wall polymer. Therapeutic failure involves acquisition of resistance, although it is a rare event among most Candida species. However, in some settings, higher-level resistance has been reported among Candida glabrata, which is also frequently resistant to azole drugs, resulting in difficult-to-treat multidrug-resistant strains. The mechanism of echinocandin resistance involves amino acid changes in \"hot spot\" regions of FKS-encoded subunits of glucan synthase, which decreases the sensitivity of enzyme to drug, resulting in higher minimum inhibitory concentration values. The cellular processes promoting the formation of resistant FKS strains involve complex stress response pathways that yield a variety of adaptive compensatory genetic responses. Standardized broth microdilution techniques can be used to distinguish FKS mutant strains from wild type, but testing C. glabrata with caspofungin should be approached cautiously. Finally, clinical factors that promote echinocandin resistance include prophylaxis, host reservoirs including biofilms in the gastrointestinal tract, and intra-abdominal infections. An understanding of clinical and molecular factors that promote echinocandin resistance is critical to develop better diagnostic tools and therapeutic strategies to overcome resistance.
Publisher
Oxford University Press
Subject
Advances and New Directions for Echinocandins
/ Antifungal Agents - pharmacokinetics
/ Antifungal Agents - pharmacology
/ Antifungal Agents - therapeutic use
/ Biofilms
/ Candida glabrata - drug effects
/ Drug Resistance, Multiple, Fungal - genetics
/ Drugs
/ Echinocandins - pharmacokinetics
/ Echinocandins - pharmacology
/ Echinocandins - therapeutic use
/ Fungi
/ Glucosyltransferases - antagonists & inhibitors
/ Glucosyltransferases - genetics
/ Humans
/ Intraabdominal Infections - drug therapy
/ Intraabdominal Infections - microbiology
/ Lipopeptides - therapeutic use
/ Mutation
/ Polymers
